Program – Hall B

Thursday, September 5, 2019

06:45-08:00
Morning Industry Symposium: 
Supported by Endomag
Breakfast will be served prior to the session
Hall B
Chairpersons    
09:30-10:30 Session 5: Imaging / Screening
Hall B
Chairpersons Bruce Mann, Australia
Nola M. Hylton, USA
09:30 -09:45 MRI screening in women without hereditary risk
Ritse Mann, The Netherlands
09:45-09:55 The implications of a move to MRI screening
Allison Rose, Australia
09:55-10:15 Debate: That women with low risk for breast cancer should only be screened every 3 years
09:55 Yes: Andrea LaCroix, USA
10:05 No:  Heather Greenwood, USA
10:15-10:30 Panel discussion:
Andrea LaCroix, USA
Ritse Mann, The Netherlands
Allison Rose, Australia
Heather Greenwood, USA
10:30-11:00 Coffee break and poster viewing  
Chairpersons    
11:00-12:30 Session 7: DCIS Hall B
Chairpersons Hiram S. Cody, USA
Donna Pinto, USA
11:00-11:35 Debate: That most DCIS should not be a target for screening
11:00 Yes: Laura Esserman, USA
11:10 No: Bruce Mann, Australia
11:20


Discussion


11:35-12:10 Debate: Most patients with DCIS should not have radiotherapy after Breast Conserving Surgery
11:35 Yes: Alastair Thompson, USA
11:45 No: Thomas A. Buchholz, USA
11:55 Discussion
12:10-12:30 Role of genomic assays in DCIS
Rita Mukhtar, USA
12:30-14:00 Lunch break and poster viewing  
Chairpersons    
14:00-15:30 Session 9:
Free Papers: Oncoplastic/Imaging*
Hall B
14:00-14:10
14:10-14:20
14:20-14:30
14:30-14:40
14:40-14:50
14:50-15:00
15:00-15:10
15:10-15:20
15:20-15:30

* This is a non CME session

15:30-16:00 Coffee break and poster viewing  
Chairpersons    
16:00-17:30 Session 11:
Free Papers: Medical Oncology*
Hall B
16:00-16:10
16:10-16:20
16:20-16:30
16:30-16:40
16:40-16:50
16:50-17:00
17:00-17:10
17:10-17:20
17:20-17:30

* This is a non CME session

17:30-18:30 Poster Session Poster area
Chairpersons    

Friday, September 6, 2019

06:45-08:00
Morning Industry Symposium:
Identifying the right patients for chemotherapy in ER+ HER2- breast cancer 

Supported by Genomic Health
Breakfast will be served prior to the session
Hall B
Chairpersons    
08:00-09:30 Session 13: Imaging as locoregional staging Hall B
Chairpersons Alastair Thompson, USA
Allison Rose, Australia
08:00-08:35 Debate: That axillary ultrasound is an essential part of early breast cancer workup
08:20 Yes: Debra M. Ikeda, USA
08:20 No: Hiram S. Cody, USA
08:20


Discussion


08:35-09:15 Debate: That contrast imaging should be part of the workup of early breast cancer
08:35 Yes: Christiane Kuhl, Germany
08:45 No: Michael Alvarado, USA
08:55 Discussion
09:15-09:30 Intraoperative imaging
Julia Camps-Herrero, Spain
09:30-10:30 Session 15: Management of impalpable lesions Hall B
Chairpersons Judy C. Boughey, USA
Amit Agrawal, UK
09:30-09:40 Why we need to change
Bruce Mann, Australia
09:40-09:50 The case for Magtrace
Michael Alvarado, USA
09:50-10:00 The case for ICG
Ava Kwong, Hong Kong
10:00-10:10 The case for Seeds
Abigail S. Caudle, USA
10:10-10:20 The case for radar localization (Savi Scout)
Tanya Moseley,
USA
10:20-10:30 Discussion
10:30-11:00 Coffee break and poster viewing  
Chairpersons    
13:45-15:15 Session 18: Metastatic Breast Cancer Hall B
Chairpersons Mark Pegram, USA
Alistair Ring,
UK
13:45-14:20 Debate: CDK 4/6 inhibitors should be first line therapy for all patients with newly diagnosed HR+ MBC
13:45 Yes: Stephen Chia, Canada
13:55 No: Mariana Chavez MacGregor, USA
14:05 Discussion
14:20-14:40 What is the approach for patients progressing on CDK 4/6 inhibitors?
Angela DeMichele, USA
14:40-15:15 Debate: ctDNA is now the best method to monitor response in patients with metastatic breast cancer
14:40 Yes: Kevin Kalinsky, USA
14:50 No: Antonio Llombart, Spain
15:00 Discussion